Tranylcypromine versus imipramine in anergic bipolar depression



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via HighWire
	Citing Articles via Google Scholar



	Articles by Himmelhoch, J. M.
	Articles by Houck, P.
	Search for Related Content



	PubMed Citation
	Articles by Himmelhoch, J. M.
	Articles by Houck, P.

Am J Psychiatry 1991; 148:910-916
Copyright © 1991 by American Psychiatric Association

BRIEF REPORTS

Tranylcypromine versus imipramine in anergic bipolar depression

JM Himmelhoch, ME Thase, AG Mallinger and P Houck
Department of Psychiatry, University of Pittsburgh School of Medicine, PA.

OBJECTIVE: This investigation compared the efficacy of the monoamine oxidase inhibitor (MAOI) tranylcypromine with that of the tricyclic imipramine in the treatment of anergic bipolar depressive illness. METHOD: A controlled, double-blind comparison was used to study 56 outpatients who met operationalized criteria for anergic bipolar depression. Patients with bipolar I and II depression were equally distributed between comparison groups. Outcome was measured by the patient-rated Beck Depression Inventory and the clinician-rated Hamilton Rating Scale for Depression, Raskin Mania and Depression Scales, Clinical Global Impression Scale, and the Pittsburgh Reversed Vegetative Symptom Scale. Twenty-eight patients were treated with tranylcypromine and 28 with imipramine. Seventy-three percent of bipolar depressive patients screened for the study met criteria for anergic depression, consistent with previous findings from studies in bipolar illness that stretch back over 100 years. RESULTS: Tranylcypromine produced statistically significant superior outcome in terms of lower attrition, greater symptomatic improvement, and higher global response without increased risk of treatment-emergent hypomania or mania. CONCLUSIONS: The authors propose that the apparently superior efficacy of tranylcypromine in bipolar depression is specifically linked to anergia and reversed neurovegetative symptoms. Bipolar I and bipolar II patients had comparable outcomes, but bipolar I patients had a significantly greater risk of treatment-emergent mood swings. Although the relatively poor showing of imipramine warrants close scrutiny, these findings provide further documentation of the utility of MAOIs in patients presenting with anergia, motor retardation, hyperphagia, and/or hypersomnia.

This article has been cited by other articles:

M. A. Frye, G. Helleman, S. L. McElroy, L. L. Altshuler, D. O. Black, P. E. Keck Jr., W. A. Nolen, R. Kupka, G. S. Leverich, H. Grunze, et al.
Correlates of Treatment-Emergent Mania Associated With Antidepressant Treatment in Bipolar Depression
Am J Psychiatry, February 1, 2009; 166(2): 164 - 172.
[Abstract] [Full Text] [PDF]

A. J. Azzaro, C. M. VanDenBerg, L. F. Blob, E. M. Kemper, M. Sharoky, D. A. Oren, and B. J. Campbell
Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects.
J. Clin. Pharmacol., August 1, 2006; 46(8): 933 - 944.
[Abstract] [Full Text] [PDF]

R. M. Post, L. L. Altshuler, G. S. Leverich, M. A. Frye, W. A. Nolen, R. W. Kupka, T. Suppes, S. McElroy, P. E. Keck, K. D. Denicoff, et al.
Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline
The British Journal of Psychiatry, August 1, 2006; 189(2): 124 - 131.
[Abstract] [Full Text] [PDF]

A. A. Nierenberg, M. J. Ostacher, J. R. Calabrese, T. A. Ketter, L. B. Marangell, D. J. Miklowitz, S. Miyahara, M. S. Bauer, M. E. Thase, S. R. Wisniewski, et al.
Treatment-Resistant Bipolar Depression: A STEP-BD Equipoise Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone
Am J Psychiatry, February 1, 2006; 163(2): 210 - 216.
[Abstract] [Full Text] [PDF]

P. J. Cowen
New drugs, old problems: REVISITING... PHARMACOLOGICAL MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION
Adv. Psychiatr. Treat., January 1, 2005; 11(1): 19 - 27.
[Abstract] [Full Text] [PDF]

S. Frangou
Advancing the pharmacological treatment of bipolar depression
Adv. Psychiatr. Treat., January 1, 2005; 11(1): 28 - 37.
[Abstract] [Full Text] [PDF]

H. J. Gijsman, J. R. Geddes, J. M. Rendell, W. A. Nolen, and G. M. Goodwin
Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
Am J Psychiatry, September 1, 2004; 161(9): 1537 - 1547.
[Abstract] [Full Text] [PDF]

J. F. Goldberg, K. E. Burdick, and C. J. Endick
Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizers for Treatment-Resistant Bipolar Depression
Am J Psychiatry, March 1, 2004; 161(3): 564 - 566.
[Abstract] [Full Text] [PDF]

M. S. Bauer and L. Mitchner
What Is a "Mood Stabilizer"? An Evidence-Based Response
Am J Psychiatry, January 1, 2004; 161(1): 3 - 18.
[Abstract] [Full Text] [PDF]

L. Altshuler, T. Suppes, D. Black, W. A. Nolen, P. E. Keck Jr., M. A. Frye, S. McElroy, R. Kupka, H. Grunze, J. Walden, et al.
Impact of Antidepressant Discontinuation After Acute Bipolar Depression Remission on Rates of Depressive Relapse at 1-Year Follow-Up
Am J Psychiatry, July 1, 2003; 160(7): 1252 - 1262.
[Abstract] [Full Text] [PDF]

L. T. Young, R. T. Joffe, J. C. Robb, G. M. MacQueen, M. Marriott, and I. Patelis-Siotis
Double-Blind Comparison of Addition of a Second Mood Stabilizer Versus an Antidepressant to an Initial Mood Stabilizer for Treatment of Patients With Bipolar Depression
Focus, January 1, 2003; 1(1): 34 - 36.
[Abstract] [Full Text] [PDF]

R. M.A. Hirschfeld, C. L. Bowden, M. J. Gitlin, P. E. Keck, R. H. Perlis, T. Suppes, M. E. Thase, and K. D. Wagner
Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision)
Focus, January 1, 2003; 1(1): 64 - 110.
[Full Text] [PDF]

J. A. Bodkin and J. D. Amsterdam
Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients
Am J Psychiatry, November 1, 2002; 159(11): 1869 - 1875.
[Abstract] [Full Text] [PDF]

R. S. El-Mallakh and A. Karippot
Use of Antidepressants to Treat Depression in Bipolar Disorder
Psychiatr Serv, May 1, 2002; 53(5): 580 - 584.
[Abstract] [Full Text] [PDF]

C. B. Nemeroff, D. L. Evans, L. Gyulai, G. S. Sachs, C. L. Bowden, I. P. Gergel, R. Oakes, and C. D. Pitts
Double-Blind, Placebo-Controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression
Am J Psychiatry, June 1, 2001; 158(6): 906 - 912.
[Abstract] [Full Text] [PDF]

I. D. Glick, T. Suppes, C. DeBattista, R. J. Hu, and S. Marder
Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia
Ann Intern Med, January 2, 2001; 134(1): 47 - 60.
[Abstract] [Full Text] [PDF]

L. T. Young, R. T. Joffe, J. C. Robb, G. M. MacQueen, M. Marriott, and I. Patelis-Siotis
Double-Blind Comparison of Addition of a Second Mood Stabilizer Versus an Antidepressant to an Initial Mood Stabilizer for Treatment of Patients With Bipolar Depression
Am J Psychiatry, January 1, 2000; 157(1): 124 - 126.
[Abstract] [Full Text]

H. S. Akiskal, J. D. Maser, P. J. Zeller, J. Endicott, W. Coryell, M. Keller, M. Warshaw, P. Clayton, and F. Goodwin
Switching From 'Unipolar' to Bipolar II: An 11-Year Prospective Study of Clinical and Temperamental Predictors in 559 Patients
Arch Gen Psychiatry, February 1, 1995; 52(2): 114 - 123.
[Abstract] [PDF]

L. H. Price and G. R. Heninger
Lithium in the Treatment of Mood Disorders
N. Engl. J. Med., September 1, 1994; 331(9): 591 - 598.
[Full Text]

Get information about faster international access.